Hematology CROs

Mid-size global CRO under ALTEN Group formed by integrating Cmed and Larix, with deep oncology, rare disease, and cell/gene therapy clinical trial expertise across the US and Europe.

Phase I-III oncology CRO providing clinical trial management with deep oncology expertise for small and mid-size pharma and biotech sponsors.

UK-based specialist oncology CRO providing early-phase clinical trial management, tumour genomics, and biomarker-driven trial design for immuno-oncology programmes.

Full-service, technology-enabled oncology-focused CRO serving biotechnology and pharmaceutical companies across all clinical phases from Wilmington, Delaware.

Precision oncology CRO using patient-derived orthotopic xenograft models and predictive AI to guide drug selection and oncology development decisions.

AI-enabled precision oncology CRO using patient-derived xenograft models and ex vivo pharmacology to generate predictive therapeutic response data for drug developers.

Preclinical oncology CRO using patient-derived tumor models and TumorGraft technology for in vivo efficacy studies, providing translational research services for oncology drug development.

US-based CRO specializing in rare disease and pediatric clinical trials, providing end-to-end trial management with deep expertise in orphan drug development and regulatory strategy.

Chinese CRO-turned-biotech providing clinical development services with deep oncology expertise, operating a portfolio of discovery through Phase III programs in solid tumors and hematological malignancies.

Global full-service CRO specializing in oncology, rare disease, and complex clinical trials across all development phases, with 2,900+ clinical research professionals operating in 100+ countries.

Specialty reference laboratory providing clinical trial testing services including infectious disease biomarker analysis, transplant diagnostics, and immunogenicity testing for clinical studies.

Leading MEA and Pakistan CRO with 140+ employees that has conducted 300+ clinical trials in 35 countries spanning the Middle East, Africa, Pakistan, and the Eurasian Economic Union.

Oncology CRO founded by oncology thought-leaders specializing in Phase I and II immuno-oncology trials in North America and Europe.

Specialist CDMO for cell and gene therapy products offering GMP clinical and commercial manufacturing and development solutions for ATMPs from German, US, and Japanese facilities.

German preclinical oncology CRO providing patient-derived xenograft models, ex vivo tumor assays, and in vivo efficacy studies for oncology drug development programs.

Swiss full-service CRO operating in 56 countries with 3,000 staff, specializing in pivotal Phase II-III clinical trials in oncology, hematology, multiple sclerosis, and rare diseases.

Specialty CRO focused on oncology and rare disease with 2,000+ professionals, known for biomarker-driven trial design, companion diagnostics, and translational research services.

Regional full-service CRO established in Egypt conducting international clinical trials, real-world evidence, and health economic studies across the Middle East and North Africa.

ISO 9001-certified Nigerian CRO with offices in Lagos and Nairobi specialising in Phase III-IV clinical trials, pharmacovigilance, and regulatory affairs across Africa.

Singapore's national academic clinical research organization supporting investigator-initiated and industry-sponsored clinical trials across Southeast Asia with strong oncology expertise.

Full-service oncology-focused CRO with 40+ years managing early-phase oncology studies for the National Cancer Institute and biopharma sponsors.

South Korean genomics and CRO company providing next-generation sequencing, genomic analysis, and precision medicine research services alongside clinical biomarker and pharmacogenomics programs.

Oncology-focused CRO founded on the Mayo Clinic campus offering preclinical-to-clinical oncology development with PDX models, flow cytometry, and Phase I/II trial management.

WuXi AppTec's cell and gene therapy division providing GMP viral vector manufacturing, cell therapy manufacturing, and plasmid DNA production from US and China facilities.

Lagos-based pioneer indigenous African CRO delivering Phase I-IV clinical trials with a focus on vaccines, neglected tropical diseases, oncology, and rare diseases across Sub-Saharan Africa.